NCT03504423 2023-01-03Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the PancreasCornerstone PharmaceuticalsPhase 3 Completed528 enrolled 11 charts